
- Member
- Find a Provider
- Claims
- FAQ
- Coordinators
- Providers
Covered Uses: | All FDA-approved indications not otherwise excluded from Part D. Additional off-label coverage is provided for treatment at the time of a first demyelinating event. |
Exclusion Criteria: | Treatment of primary progressive MS is not covered. Combination therapy with a beta interferon product, Gilenya, or Copaxone is not covered. |
Required Medical Information: | For relapsing forms of multiple sclerosis: Patient must still either be able to walk at least a few steps or alternatively must have some functional arm/ hand use consistent with performing activities of daily living. For Rebif only, patients must be already receiving Rebif or have experienced intolerance/failure with glatiramer (Copaxone), interferon beta-1b (Betaseron) or Interferon beta-1a (Avonex). |
Age Restrictions: | |
Prescriber Restrictions: | |
Coverage Duration: | 12 months |
Other Criteria: |